Sanofi (SNY) Loses 9% as New Drug Candidate Appears Weaker Than Predecessor

We recently published 10 Major Stocks Collapse. Sanofi (NASDAQ:SNY) is one of the worst performers on Thursday.

Sanofi snapped a two-day winning streak on Thursday, shedding 9.14 percent to end at $45.33 apiece following the results of its drug candidate Amlitelimab that fell short of its predecessor’s benchmark.

In a statement, Sanofi (NASDAQ:SNY) said it was able to achieve its primary endpoints for its drug candidate, Amlitelimab, having demonstrated statistically significant and clinically meaningful skin clearance and disease severity compared to placebo at Week 24 in patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).

Sanofi (SNY) Loses 9% as New Drug Candidate Appears Weaker Than Predecessor

It said that the drug candidate was well tolerated, without any safety concerns identified in the study.

However, Amlitelimab fell short of Dupixent’s benchmark, which, during its Phase 3 trial, already achieved promising results at Week 16, suggesting that it was way weaker than its predecessor.

According to Sanofi (NASDAQ:SNY), full results will be submitted for presentation at an upcoming medical meeting.

While we acknowledge the risk and potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.